Hospital Universitario de Getafe

The trials here

What the 21 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• Alzheimer disease2 trials
• Multiple sclerosis2 trials
• Type 2 diabetes2 trials
• Atrial fibrillation1 trial
• Bladder cancer1 trial
• Bronchiectasis1 trial
• Coronary artery disease1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Heart failure1 trial
• HIV1 trial
• and 10 more

Phase

• Phase 37 trials
• Phase 24 trials
• Phase 42 trials

Status

• Completed8 trials
• Recruiting7 trials
• Active, not recruiting3 trials
• Not yet recruiting3 trials

Lead sponsor

• Hospital Universitari Vall d'Hebron Research Institute2 trials
• Novo Nordisk A/S2 trials
• AbbVie1 trial
• Biogen1 trial
• Boehringer Ingelheim International GmbH1 trial
• and 14 more

Running trials

• Not yet recruiting

  PRIME Trial - Primary Respiratory Infection and Microbiological Eradication Trial

  2025-524454-34-00· Phase 4· Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Enrolling by invitation

  FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors

  NCT07181135· Phase 3· University Medical Center Groningen· Source

• Recruiting

  A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

  NCT07202546· Phase 2· ViiV Healthcare· Source

• Recruiting

  NOPE37: Angiogenic Factors for Managing Term Preeclampsia

  NCT07193680· Hospital Universitari Vall d'Hebron Research Institute· Source

  Contact: Elena Pintado

• Recruiting

  A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease

  2024-513035-25-00· Phase 2· Intra-Cellular Therapies Inc.· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

  NCT06724159· Spanish Oncology Genito-Urinary Group· Source

  Contact: Designated by the Sponsor

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source

• Not yet recruiting

  Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

  NCT05284474· Hospital Universitari Vall d'Hebron Research Institute· Source

  Contact: Elena Pintado

• Active, not recruiting

  A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

  NCT06118411· Phase 3· AbbVie· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

  NCT05147220· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Spanish Series of Patients Treated With the Radionuclide Lutetium177

  NCT04949282· Sociedad Española de Medicina Nuclear e Imagen Molecular· Source

  Contact: Mercedes Dr Mitjavila Casanovas, MD-PhD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease2 recruiting
• Bladder cancer1 recruiting
• Bronchiectasis1 recruiting
• Chronic kidney disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Multiple sclerosis1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

  NCT06717698· Phase 2· Novo Nordisk A/S· Source

• Completed

  Augmented Reality as Discharge Information for Hospitalized Cardiology Patients

  NCT07399379· Hospital Universitario Getafe· Source

• Completed

  Development of a Molecular Diagnostic Tool for Endometrial Cancer.

  NCT06192017· MiMARK Diagnostics, S.L.· Source

• Completed

  Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria

  NCT05732506· Galaxia Empírica· Source

• Completed

  A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study

  2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source

• Completed

  A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

  NCT04763408· Eisai Inc.· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source